Member Info for 1902

https://www.**********.co.uk/rns/announcement/93e791b9-6db0-4269-a0e4-49a21a30d352/

And there it is:

"Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor ("CBR") platform technology, designed to program immune cells to eliminate viral infections by destroying the viruses that cause them. The Company's scientists have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus. Among them are Dengue, Ebola, Marburg, Zika and Chikungunya. These viruses are among the most dangerous to humans, causing serious and often fatal diseases, and for which few effective treatment options exist.

...

CBR allows the development of:

(1) off-the-shelf cell therapies against infectious disease.

(2) biopharmaceuticals to eliminate any potential virus in the course of infection or to be used as a preventive treatment"

These things stood out to me. Happy Monday to all!

Pedro - not a bad idea. I began trading this one through the 500s and 600s in the summer after spotting the same as you. By doing this I have managed to increase my position here, increase my positions in two other companies (admittedly by only a small amount) and cover two mortgage payments. That said, my last tranche here is down by 8% as I type this, so it's a waiting game again for me now on that one. I've found focusing on the movements and patterns of just one or two companies has given me much more success than the reckless chasing I used to do.

Tatty, in local authority (in my experience of doing them) they have been binding. So perhaps they are elsewhere.

It is absolutely quite certain in its tone, for sure. And as these things are supposed to be truthful, especially for a FTSE company......

was not* the case this time

HT - I think the difference being that Vlad/Hemogenyx was presenting at the H.C. Wainwright conferences, which was the case at the BCB meeting.

Of course, Hemogenyx is not on AIM.

Lioness - That's what I'm now wondering too. Fingers crossed for sure, though I have now written this off (mentally) as a 100% loss. Would be wonderful to get something back..

one2one - a very strong message of confidence. I can't see that comment being made from him without some expectation that this is a product that will (or perhaps already does but they can't say in advance of due process completing) work.

It's an exciting time to be invested here for sure.

I've read the RNSs, I've watched the presentations, I've attended Q&As, I've reviewed progress by other teams in related/same fields, I've considered the views and concerns of posters on this board.

My conclusion: I'm with JHFH and some others on here and not in this for the short-term. All IMO. Have a nice afternoon Pumpky.

MrI - I do, so I did at 10:36. I can well imagine that 200K shares here will be worth £200K somewhere along the line.

MrI - I'll buy 200K shares this morning if that'll make you feel more positive about HEMO today...

It could quite possibly be what you say.
In any case, it looks like I misjudged a little and should have topped up more back in the 42s. I'll still wait a while and perhaps add on any pullbacks, though I do feel positive from these levels.

I wondered that - it's on my watchlist and I was going to add a few later today or certainly within the next few sessions. Something tells me it will go up further and then retrace either much of it today or tomorrow morning if nothing's announced. I'll hold off a little while longer.

draft - As far as I am aware I am neither blind nor lying, though I am overdue an eye test and replacement glasses. I have copied the first sentence below. I believe the third from last word is 'Bayer', but I could be wrong, as I often am.

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform.

draft - it is in the first sentence of today's RNS.

Hi Jap - I don't think it would be wise for anyone to advise you personally on your question.
However for myself, I have lurked in the background for a long time, watching the share price fall from highs of the 1250s/60s last Autumn to lows in the high 400s in Feb and June this year. All the while a range of good news has been issued further strengthening the company's offer and future potential in what is an increasingly high profile sector - read recent RNSs for more details on these.
I bought my first tranche last month in the 520s and have added (and sold in order to increase my position) at various points as it's wobbled through the 500s. I'm glad I did; to me the the company is well run, has a great offer and the direction is fairly clear (to me) from this point. You and others on here may come to a different conclusion based on your own research.
On that note I'm very grateful to the regular posters on this board who have provided some great commentary. Worth going back through a few months posts to find more about the story.

The invite asks that the link is not shared publicly so please contact Charles Goodfellow at cg @ peterhousecap. com

Take out the spaces.

MrIndia - you're definitely right that a larger audience will make it different. I think it was only the 5 of us in the Zoom last time so it was a focussed discussion.
If I can make it (i.e. work not get in the way) I look forward to seeing some of you there :)

MrIndia - Best not to pin hopes on the webinar, but stay patient for the updates coming over the next weeks, months and year or two.